Skip to main content

Table 2 Clinical effectiveness evaluation at each follow-up time point

From: Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study

 

IVMP (n = 29)

Tacrolimus (n = 28)

Estimated difference (95% CI)a

p value

QMG, median (IQR) 1 month after treatment

Ocular QMG score

3 (1, 4)

4 (3, 5)

–1 (– 2, 0)

0.078

QMG score for diplopia

1 (0, 3)

1 (0, 3)

0 (0, 0)

0.704

QMG score for ptosis

1 (0, 1.5)

2 (1, 3)

–1 (– 2, 0)

0.004**

QMG score for eyelid closure

0 (0, 1)

1 (0, 1)

0 (0, 0)

0.511

∆QMG score (baseline—1 month)

∆Ocular QMG score

2 (0, 3.5)

0 (0, 1)

1 (0, 2)

0.001**

∆QMG score for diplopia

0 (0, 0)

0 (0, 0)

0 (0, 0)

0.710

∆QMG score for ptosis

1 (0, 2)

0 (0, 0)

1 (0, 2)

 < 0.001***

∆QMG score for eyelid closure

0 (0, 1)

0 (0, 0)

0 (0, 1)

0.030*

3 months after treatment

Ocular QMG score

3 (1, 4)

3 (1, 4)

0 (– 1, 1)

0.580

QMG score for diplopia

1 (0, 3)

0 (0, 2.5)

0 (0, 1)

0.339

QMG score for ptosis

1 (0, 1.5)

1 (0, 3)

0 (– 1, 0)

0.100

QMG score for eyelid closure

0 (0, 1)

1 (0, 1)

0 (– 1, 0)

0.210

∆QMG score (baseline—3 months)

∆Ocular QMG score

2 (1, 3.5)

1 (0, 3)

1 (0, 2)

0.132

∆QMG score for diplopia

0 (0, 0.5)

0 (0, 2)

0 (0, 0)

0.575

∆QMG score for ptosis

1 (1, 2)

0.5 (0, 1)

1 (0, 1)

0.018*

∆QMG score for eyelid closure

0 (0, 1)

0 (0, 0)

0 (0, 1)

0.015*

∆QMG score (1 month—3 months)

∆Ocular QMG score

0 (0, 1)

1 (0, 3)

–1 (–1, 0)

0.019*

∆QMG score for diplopia

0 (0, 0)

0 (0, 2)

0 (0, 0)

0.038*

∆QMG score for ptosis

0 (0, 0)

0 (0, 1)

0 (-1, 0)

0.020*

∆QMG score for eyelid closure

0 (0, 0)

0 (0, 0)

0 (0, 0)

0.399

6 months after treatment

Ocular QMG score

3 (1, 4.5)

1.5 (1, 3)

0 (– 1, 2)

0.431

QMG score for diplopia

0 (0, 3)

0 (0, 0.75)

0 (0, 1)

0.086

QMG score for ptosis

1 (0, 2)

1 (0, 2)

0 (– 1, 0)

0.609

QMG score for eyelid closure

0 (0, 1)

0 (0, 1)

0 (0, 0)

1.000

∆QMG score (baseline—6 months)

∆Ocular QMG score

2 (1, 3)

1 (0.25, 4)

0.5 (– 1, 2)

0.432

∆QMG score for diplopia

0 (0, 1.5)

0 (0, 3)

0 (0, 0)

0.496

∆QMG score for ptosis

1 (0.5, 2)

1 (0, 1.75)

0 (0, 1)

0.126

∆QMG score for eyelid closure

0 (0, 1)

0 (0, 1)

0 (0, 1)

0.102

∆QMG score (3 months—6 months)

∆Ocular QMG score

0 (0, 0)

0 (0, 1)

0 (– 1, 0)

0.054

∆QMG score for diplopia

0 (0, 0)

0 (0, 0)

0 (0, 0)

0.477

∆QMG score for ptosis

0 (0, 0)

0 (0, 0)

0 (0, 0)

0.129

∆QMG score for eyelid closure

0 (0, 0)

0 (0, 0)

0 (0, 0)

0.018*

  1. IVMP, intravenous methylprednisolone; QMG, quantitative myasthenia gravis; IQR, interquartile range; CI, confidence interval; *p < 0.05; **p < 0.01; ***p < 0.001
  2. aBetween-group differences are expressed as a pseudo-median difference calculated with the use of the Hodges–Lehmann estimate based on the Mann–Whitney U test
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172